These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 80422)

  • 1. Antigen-specific regulation of myeloma cell differentiation in vivo by carrier-specific T cell factors and macrophages.
    Rohrer JW; Lynch RG
    J Immunol; 1978 Sep; 121(3):1066-74. PubMed ID: 80422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulation of localized and disseminated murine myeloma: antigen-specific regulation of MOPC-315 stem cell proliferation and secretory cell differentiation.
    Rohrer JW; Lynch RG
    J Immunol; 1979 Sep; 123(3):1083-7. PubMed ID: 89159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific, immunologic regulation of differentiation of immunoglobulin expression in MOPC-315 cells during in vivo growth in diffusion chambers.
    Rohrer JW; Lynch RG
    J Immunol; 1977 Dec; 119(6):2045-53. PubMed ID: 72116
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes.
    Flood PM; Philipps C; Taupier MA; Schreiber H
    J Immunol; 1980 Jan; 124(1):424-30. PubMed ID: 6965296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoregulation of murine myeloma: isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo.
    Rohrer JW; Odermatt B; Lynch RG
    J Immunol; 1979 May; 122(5):2011-9. PubMed ID: 87450
    [No Abstract]   [Full Text] [Related]  

  • 6. T cells with FC receptors in myeloma; suppression of growth and secretion of MOPC-315 by T alpha cells.
    Müller S; Hoover RG
    J Immunol; 1985 Jan; 134(1):644-7. PubMed ID: 3871117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
    Chow KP; Battisto JR
    J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype-specific T cell suppression of light chain mRNA expression in MOPC-315 cells is accompanied by a posttranscriptional inhibition of heavy chain expression.
    Milburn GL; Parslow TG; Goldenberg C; Granner DK; Lynch RG
    J Mol Cell Immunol; 1984; 1(2):115-23. PubMed ID: 6242851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell responses induced by the parenteral injection of antigen-modified syngeneic cells. I. Induction, characterization, and regulation of antigen-specific T helper cells involved in delayed-type hypersensitivity responses.
    Miller SD; Butler LD
    J Immunol; 1983 Jul; 131(1):77-85. PubMed ID: 6190929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of help and suppression in a hapten-carrier system.
    Eardley DD; Sercarz EE
    J Immunol; 1976 Mar; 116(3):600-5. PubMed ID: 56397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T lymphocyte-mediated suppression of myeloma function in vitro. I. Suppression by allogeneically activated T lymphocytes.
    Abbas AK
    J Immunol; 1979 Nov; 123(5):2011-8. PubMed ID: 114584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte surface membrane immunoglobulin in myeloma. I. M315-bearing T lymphocytes in mice with MOPC-315.
    Gebel HM; Hoover RG; Lynch RG
    J Immunol; 1979 Sep; 123(3):1110-6. PubMed ID: 313945
    [No Abstract]   [Full Text] [Related]  

  • 14. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Origin and function of suppressor macrophages in myeloma.
    Kennard J; Zolla-Pazner S
    J Immunol; 1980 Jan; 124(1):268-73. PubMed ID: 6965292
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunoglobulin-dependent helper T cells: studies in the MOPC-315 system suggest a novel surface antigen phenotype.
    Rohrer JW; Kemp JD
    J Immunol; 1986 Sep; 137(6):1786-92. PubMed ID: 2943802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
    Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
    J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessory cells in the in vitro generation of type C virus-specific T killer lymphocytes. II. Demonstration of a T helper cell in the spleen of in vivo primed mice.
    Gomard E; Wybier-Franqui J; Simmler MC; McKenzie IF; Levy JP
    J Immunol; 1981 Dec; 127(6):2291-5. PubMed ID: 6170695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.